• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Celgene Corporation

Celgene Corporation

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Innovation, not easy money, is behind the Nasdaq's return to 5,000

    Innovation, not easy money, is behind the Nasdaq's return to 5,000

  2. Research and Markets: Metastatic Pancreatic Cancer Pipeline Review 2015 - Analysis of 46 Companies & 66 Drug Profiles

    Research and Markets: Metastatic Pancreatic Cancer Pipeline Review 2015 - Analysis of 46 Companies & 66 Drug Profiles

  3. ADDING MULTIMEDIA REVLIMID® (Lenalidomide) Approved by the European Commission for the Treatment of Adult Patients with Previously Untreated Multiple Myeloma who are Not Eligible for Transplant

    ADDING MULTIMEDIA REVLIMID® (Lenalidomide) Approved by the European Commission for the Treatment of Adult Patients with Previously Untreated Multiple Myeloma who are Not Eligible for Transplant

  4. Charting a sluggish, but bullish, S&P 500 -2-

    Charting a sluggish, but bullish, S&P 500 -2-

  5. Oxis Biotech Inc. Provides Update for P62-ZZ Multiple Myeloma Patent Application

    Oxis Biotech Inc. Provides Update for P62-ZZ Multiple Myeloma Patent Application

  6. UPDATE: U.S. markets spike from major technical support

    UPDATE: U.S. markets spike from major technical support

  7. Share Repurchase: Potential Signal of Undervaluation and Outperformance

    Celgene's CELG prized drug Revlimid was approved for multiple myeloma in June, and third-quarter results gave us our first look at sales for its use in treating a second form of blood cancer. While Revlimid's multiple myeloma launch was strong and did not appear to cannibalize legacy drug ...

  8. Credit Market Outlook: Bonds Priced for the Benign

    Corporate credit spreads are fairly valued--albeit at the tight end of the range that we view as fairly valued.

  9. An ETF for This Lagging Sector

    Biotech companies' returns have diverged from the broader market in recent weeks amid concerns over greater regulation and price discounting.

  10. Our Outlook for the Credit Markets

    Widening investment-grade credit spreads and rising interest rates lead to losses.

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.